ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
28 February 2013 | By
Agreement brings the number of voluntary...
List view / Grid view
28 February 2013 | By
Agreement brings the number of voluntary...
27 July 2012 | By GlaxoSmithKline
Findings support progression towards registration...
21 October 2011 | By Janssen Pharmaceuticals Inc.
New HIV data to be presented at EACS 2011...
18 July 2011 | By Eli Lilly and Company
New study results released...
18 July 2011 | By Merck
Extending to nearly five years in previously untreated adults with HIV-1...
20 June 2011 | By Guihua Sun, Irell & Manella Graduate School of Biological Science and Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope and John J. Rossi. Department of Molecular and Cellular Biology Beckman Research Institute of the City of Hope
Treatment and cure of human immunodeficiency virus-1(HIV-1) infection remains one of the greatest therapeutic challenges due to its persistent infection, often leading to acquired immunodeficiency syndrome (AIDS). Although it has been 28 years since the discovery of the virus, the development of an effective vaccine is still far away. Relatively…
24 June 2010 | By Marc S. Weinberg and Fiona van den Berg, Antiviral Gene Therapy Research Unit, Department of Molecular Medicine and Haematology, University of Witwatersrand
Since the discovery of RNA interference (RNAi) in 1998 and the demonstration of RNAi in mammalian cells in 2001, research into the mechanisms and applications of this pathway has moved swiftly. RNAi is capable of mediating potent and specific silencing of genes and has therefore shown promise in the development…